Literature DB >> 1519473

Is the prevalence of Parkinson's disease in New Zealand really changing?

T H Caradoc-Davies1, M Weatherall, G S Dixon, G Caradoc-Davies, P Hantz.   

Abstract

The prevalence of idiopathic Parkinson's Disease (IPD) in Dunedin, New Zealand on 31st July 1990 was 110.4/100,000. When corrected to a standard population based on the 1960 U.S. census, the prevalence fell to 76.0/100,000 due to changes in the age structure of the population. The corrected prevalence in Wellington (another New Zealand city), in 1962 was 99.6 (before the introduction of levodopa), and in Aberdeen, Scotland in 1984 was 102.7. The principal difference was fewer people under 65 years of age in our study. Case finding methods and diagnostic criteria were similar in all three studies, and case ascertainment was adequate. Under representation of younger people could be due to either a lower incidence rate or poorer survival due to treatment with high doses of levodopa compounds. Prospective research is required to explain our findings.

Entities:  

Mesh:

Year:  1992        PMID: 1519473     DOI: 10.1111/j.1600-0404.1992.tb08051.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease.

Authors:  I Reuter; S Mehnert; P Leone; M Kaps; M Oechsner; M Engelhardt
Journal:  J Aging Res       Date:  2011-03-30

2.  Epidemiology of Parkinson's disease.

Authors:  Meike Kasten; Annabel Chade; Caroline M Tanner
Journal:  Handb Clin Neurol       Date:  2007

3.  Trends in antiparkinsonian medication use in new zealand: 1995-2011.

Authors:  T L Pitcher; M R Macaskill; T J Anderson
Journal:  Parkinsons Dis       Date:  2014-03-04

Review 4.  Mitochondria: A Therapeutic Target for Parkinson's Disease?

Authors:  Yu Luo; Alan Hoffer; Barry Hoffer; Xin Qi
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

Review 5.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner; S M Goldman
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.